256 related articles for article (PubMed ID: 22239993)
1. Plasma derivatives: new products and new approaches.
Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
Schaub RG
Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
[TBL] [Abstract][Full Text] [Related]
3. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
4. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic infusion regimens in the management of hemophilia.
Ljung RC
Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
7. The evolution of recombinant factor replacement for hemophilia.
Sankar AD; Weyand AC; Pipe SW
Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
[TBL] [Abstract][Full Text] [Related]
8. [Substitution therapy of hemorrhagic diseases].
Haupt H
Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
[No Abstract] [Full Text] [Related]
9. Innovations in coagulation: improved options for treatment of hemophilia A and B.
Pabinger-Fasching I; Pipe S
Thromb Res; 2013 Mar; 131 Suppl 2():S1. PubMed ID: 23537720
[No Abstract] [Full Text] [Related]
10. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
11. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
12. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
13. Surgery in haemophilic patients with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
[No Abstract] [Full Text] [Related]
14. The More Recent History of Hemophilia Treatment.
Franchini M; Mannucci PM
Semin Thromb Hemost; 2022 Nov; 48(8):904-910. PubMed ID: 36108649
[TBL] [Abstract][Full Text] [Related]
15. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
17. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
18. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
19. 2017 Clinical trials update: Innovations in hemophilia therapy.
Hartmann J; Croteau SE
Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
[TBL] [Abstract][Full Text] [Related]
20. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
